Comparison 8. Subgroup analysis: phase 2 versus phase 3 studies (HIF versus ESA).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
8.1 Proportion reaching target haemoglobin	14	4601	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.93, 1.07]
8.1.1 Phase 2	6	1356	Risk Ratio (M‐H, Random, 95% CI)	1.10 [0.90, 1.34]
8.1.2 Phase 3	8	3245	Risk Ratio (M‐H, Random, 95% CI)	0.97 [0.91, 1.05]
8.2 Thrombosis	11	17026	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.86, 1.39]
8.2.1 Phase 2	1	740	Risk Ratio (M‐H, Random, 95% CI)	1.11 [0.60, 2.02]
8.2.2 Phase 3	10	16286	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.83, 1.42]